Clinical Trial Detail

NCT ID NCT03854474
Title Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

transitional cell carcinoma

Therapies

Pembrolizumab + Tazemetostat

Age Groups: adult senior

Additional content available in CKB BOOST